This study is a bidirectional cohort study. The investigators conduct a bidirectional cohort study utilizing a database in mainland China, continuously collecting demographics, clinical symptoms, and biochemical characteristics of diagnosed PBC patients.

The study aims to analyze the association between varying post-treatment alkaline phosphatase (AKP) levels and complication-free survival rates, with the objective to develop and validate a predictive survival model.

Inclusion Criteria:

• Age above 18 years old, Male or Female,
• Diagnosis of PBC meeting the 2018 American Association for the Study of Liver Diseases (AASLD) Practice Guidelines criteria;
• Treatment with UDCA at a standard dose (13-15 mg/kg/day), with or without other second-line medications.

Exclusion Criteria:

• Co-existing liver diseases, including but not limited to: Hepatitis C virus infection; Active Hepatitis B infection (patients who are HBsAg-negative and HBeAg-negative may be considered eligible per investigator assessment);
• Autoimmune Hepatitis (AIH); Primary Sclerosing Cholangitis (PSC); Suspected or confirmed hepatocellular carcinoma;
• Female subjects who is pregnant or breastfeeding during the study;
• History of other malignancies, including hematological tumors, solid tumors except hepatobiliary system;
• Poor adherence or inability to complete the study follow-up.

This program will be conducted at a single medical center in Shanghai, Mainland China. The sample size of subjects will be 3000 PBC patients.

After this observational study is recruited, we are welcome to share the basic demographics and clinical outcomes of recruited IPD.